Literature DB >> 9242542

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

H R Koene1, M Kleijer, J Algra, D Roos, A E von dem Borne, M de Haas.   

Abstract

We analyzed a genetic polymorphism of Fc gamma receptor IIIa (CD16) that is present on position 158 (Phe or Val) in the membrane-proximal, IgG-binding domain. With a polymerase chain reaction-based allele-specific restriction analysis assay we genotyped 87 donors and found gene frequencies of 0.57 and 0.43 for Fc gammaRIIIA-158F and -158V, respectively. A clear linkage was observed between the Fc gammaRIIIA-158F and -48L genotypes on the one hand and the Fc gammaRIIIA-158V and -48H or -48R genotypes on the other hand (chi2 test; P < .001). To determine the functional consequences of this Fc gammaRIIIa-158V/F polymorphism, we performed IgG binding experiments with natural killer (NK) cells from genotyped donors. All donors were also typed for the recently described triallelic Fc gammaRIIIa-48L/R/H polymorphism. NK cells were treated with lactic acid to remove cell-associated IgG. Fc gammaRIIIa(NK)-158F bound significantly less IgG1, IgG3, and IgG4 than did Fc gammaRIIIa(NK)-158V, irrespective of the Fc gammaRIIIa-48 phenotype. Moreover, freshly isolated NK cells from Fc gammaRIIIa-158VV individuals carried significantly more cytophilic IgG than did NK cells from Fc gammaRIIIa-158FF individuals. In addition, CD16 monoclonal antibody (MoAb) MEM154 bound more strongly to Fc gammaRIIIa-158V, compared with -158F, again independently of the Fc gammaRIIIa-48 phenotype. The binding of MoAb B73.1 was not influenced by the Fc gammaRIIIa-158V/F polymorphism, but proved to depend solely on the amino acid present at position 48 of Fc gammaRIIIa. In conclusion, the previously reported differences in IgG binding among the three Fc gammaRIIIa-48L/R/H isoforms are a consequence of the linked, biallelic Fc gammaRIIIa-158V/F polymorphism at amino-acid position 158.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242542

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  251 in total

1.  Fcgamma receptor polymorphisms in populations in Ethiopia and Norway.

Authors:  L Van Den Berg; K M Myhr; B Kluge; C A Vedeler
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

2.  Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.

Authors:  Ralf Kircheis; Nicole Halanek; Iris Koller; Wolfgang Jost; Manfred Schuster; Gilbert Gorr; Klaus Hajszan; Andreas Nechansky
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

3.  Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.

Authors:  Daniel O Persky; David Dornan; Bryan H Goldman; Rita M Braziel; Richard I Fisher; Michael Leblanc; David G Maloney; Oliver W Press; Thomas P Miller; Lisa M Rimsza
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

4.  Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay.

Authors:  Bhavin S Parekh; Elaine Berger; Sharon Sibley; Suntara Cahya; Liqun Xiao; Melinda Ann LaCerte; Peter Vaillancourt; Scott Wooden; Dennis Gately
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

5.  Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

Authors:  Sara A Hurvitz; David J Betting; Howard M Stern; Emmanuel Quinaux; Jeremy Stinson; Somasekar Seshagiri; Ying Zhao; Marc Buyse; John Mackey; Adrian Driga; Sambasivarao Damaraju; Mark X Sliwkowski; Nicholas J Robert; Vicente Valero; John Crown; Carla Falkson; Adam Brufsky; Tadeusz Pienkowski; Wolfgang Eiermann; Miguel Martin; Valerie Bee; Omkar Marathe; Dennis J Slamon; John M Timmerman
Journal:  Clin Cancer Res       Date:  2012-04-13       Impact factor: 12.531

Review 6.  Anti-CD30 Antibodies for Hodgkin lymphoma.

Authors:  Kelley V Foyil; Nancy L Bartlett
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

7.  The rules of variation: amino acid exchange according to the rotating circular genetic code.

Authors:  Fernando Castro-Chavez
Journal:  J Theor Biol       Date:  2010-04-03       Impact factor: 2.691

8.  Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Authors:  Benjamin Joachim Schmiedel; Antje Werner; Julia Steinbacher; Tina Nuebling; Corina Buechele; Ludger Grosse-Hovest; Helmut Rainer Salih
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

Review 9.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

10.  Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity.

Authors:  Nadia Anikeeva; Maria Steblyanko; Svetlana Fayngerts; Natalya Kopylova; Deborah J Marshall; Gordon D Powers; Takami Sato; Kerry S Campbell; Yuri Sykulev
Journal:  Eur J Immunol       Date:  2014-06-05       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.